Futuremeds Sp. z o.o.
- Address
- lock Available on a paid plan
Cardiovascular Diseases and Nutritional and Metabolic Diseases
At Futuremeds Wrocław, the clinical trial portfolio focuses on cardiovascular disease and metabolic disorders, especially conditions linked to abnormal blood lipids. The research is aimed at understanding and improving care for people with hypertriglyceridemia, atherosclerosis, and broader atherosclerotic cardiovascular disease.
- Testing new approaches for lowering triglyceride levels in people with severe lipid abnormalities
- Evaluating treatments intended to reduce the risk of major cardiovascular events such as heart attack and stroke
- Studying whether new therapies can better support patients whose current lipid-lowering treatment is not enough
The site’s work reflects a strong interest in therapies that may help prevent progression of atherosclerotic heart and blood vessel disease while improving long-term cardiovascular outcomes.
Blood Lipid Research in Wroclaw
This research program at Futuremeds Sp. z o.o. centers on clinical studies of abnormal lipid metabolism and its impact on heart health. The trials are designed to assess whether investigational treatments can improve fasting triglyceride levels and provide better protection for patients at risk of cardiovascular complications.
- Exploring therapies for severe hypertriglyceridemia
- Investigating treatment options for people with established atherosclerotic cardiovascular disease
- Assessing the potential of new medicines to improve overall cardiovascular risk
With a small but focused trial base, the site contributes to research that may refine treatment strategies for patients living with persistent lipid disorders and related heart disease.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 18 therapeutic areas and 15 of 185 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 179 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 46 by active trials.
- 1AstraZeneca AB5active
lock +45 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB8trials
lock +33 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Futuremeds Sp. z o.o.
lock Showing 1 of 148 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multicenter, Randomized, Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Deucravacitinib in Adolescent Subjects (12 years to less than 18 years) with Moderate to Severe Plaque Psoriasis | Bristol-Myers Squibb Services Unlimited Company | Phase III | Recruiting | Oct 2025 | — |
IMP list
lock Showing 1 of 185 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Apremilast | 4 | Unknown | 2024-05-07 | 2025-06-26 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.